Saeedi M, et al. - Researchers conducted a randomized, placebo-controlled, clinical trial comparing three different oxygen therapy methods in primary headaches in a cohort of 136 adults with moderate-to-severe primary headaches (VAS score of ≥ 4). Participants were evenly allocated to one of four treatment groups: 30 mg of intravenous ketorolac plus oxygen at 15 L/min (min) through a non-rebreather mask; 30 mg of intravenous ketorolac plus 7 L/min of oxygen through a 60% venturi mask; 30 mg of intravenous ketorolac plus 4 L/min of oxygen through a nasal cannula; or 30 mg of intravenous ketorolac and room air. According to findings, endpoint criterion of a 1.3-cm difference on the VAS scale was not met in any of the groups after 60 minutes despite the significantly higher efficacy of the non-rebreather mask at 30 minutes.